Patent Valuation, Monetization and Investments

Posts tagged rituximab

What exactly is the standard for institution of an IPR? A recent institution decision shows the Board is not in agreement.

A recent decision by the PTAB denying institution of an IPR related to Rituxan(R) shows that disagreements exist within the PTAB over the precise standard that must be met for institution.

Markman AdvisorsNovember 17, 2017IPR, inter partes review, pfizer, biogen, rituximab, rituxan, ptab, board, patent, 172 patent, 316(a)Comment

Blog

home | team | valuation | consulting | monetization | news | blog